EA026729B1 - Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения - Google Patents

Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения Download PDF

Info

Publication number
EA026729B1
EA026729B1 EA201592287A EA201592287A EA026729B1 EA 026729 B1 EA026729 B1 EA 026729B1 EA 201592287 A EA201592287 A EA 201592287A EA 201592287 A EA201592287 A EA 201592287A EA 026729 B1 EA026729 B1 EA 026729B1
Authority
EA
Eurasian Patent Office
Prior art keywords
formula
compounds
carbazole
carboxamide
dioxo
Prior art date
Application number
EA201592287A
Other languages
English (en)
Russian (ru)
Other versions
EA201592287A1 (ru
Inventor
Джозеф А. Тино
Анураг С. Сривастава
Соо Сун Ко
Майкл А. Галелла
Чарльз М. Лангевайн
Джордж В. Делукка
Цинцзе Лю
Дуглас Г. Батт
Скотт Хантер Уотерсон
Цин Ши
Мира Бодуа Бертран
Original Assignee
Бристол-Майерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Майерс Сквибб Компани filed Critical Бристол-Майерс Сквибб Компани
Publication of EA201592287A1 publication Critical patent/EA201592287A1/ru
Publication of EA026729B1 publication Critical patent/EA026729B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
EA201592287A 2013-06-25 2014-06-25 Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения EA026729B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361839141P 2013-06-25 2013-06-25
PCT/US2014/043978 WO2014210085A1 (en) 2013-06-25 2014-06-25 Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201592287A1 EA201592287A1 (ru) 2016-06-30
EA026729B1 true EA026729B1 (ru) 2017-05-31

Family

ID=51210830

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201592287A EA026729B1 (ru) 2013-06-25 2014-06-25 Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения

Country Status (31)

Country Link
US (6) US9334290B2 (index.php)
EP (1) EP3013814B1 (index.php)
JP (1) JP6353529B2 (index.php)
KR (1) KR102346508B1 (index.php)
CN (1) CN105358546B (index.php)
AR (1) AR096721A1 (index.php)
AU (1) AU2014302548B2 (index.php)
BR (1) BR112015030723A8 (index.php)
CA (1) CA2916500A1 (index.php)
CL (1) CL2015003635A1 (index.php)
CY (1) CY1119371T1 (index.php)
DK (1) DK3013814T3 (index.php)
EA (1) EA026729B1 (index.php)
ES (1) ES2636652T3 (index.php)
HR (1) HRP20171031T1 (index.php)
HU (1) HUE034460T2 (index.php)
IL (1) IL243296B (index.php)
LT (1) LT3013814T (index.php)
MA (1) MA38648B1 (index.php)
MY (1) MY176631A (index.php)
PE (1) PE20160519A1 (index.php)
PH (1) PH12015502630A1 (index.php)
PL (1) PL3013814T3 (index.php)
PT (1) PT3013814T (index.php)
RS (1) RS56371B1 (index.php)
SI (1) SI3013814T1 (index.php)
SM (1) SMT201700422T1 (index.php)
TN (1) TN2015000529A1 (index.php)
TW (1) TWI648272B (index.php)
UY (1) UY35625A (index.php)
WO (1) WO2014210085A1 (index.php)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2916504A1 (en) 2013-06-25 2014-12-31 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
PT3461821T (pt) 2014-10-24 2020-08-05 Bristol Myers Squibb Co Compostos de indol carboxamida úteis como inibidores de quinase
AU2015335783B2 (en) 2014-10-24 2019-10-03 Bristol-Myers Squibb Company Tricyclic atropisomer compounds
TWI676618B (zh) * 2014-10-24 2019-11-11 美商必治妥美雅史谷比公司 三環化合物
EP3478148B1 (en) 2016-07-01 2021-08-04 Brio Device LLC Intubation stylet with video feed
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
WO2018102785A2 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
KR102462896B1 (ko) * 2016-12-20 2022-11-02 브리스톨-마이어스 스큅 컴퍼니 테트라히드로카르바졸 카르복스아미드 화합물의 제조 방법
WO2019208805A1 (ja) 2018-04-27 2019-10-31 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
KR102653681B1 (ko) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
MX2024009770A (es) * 2022-02-15 2024-08-19 Hoffmann La Roche Procesos para la preparacion de derivados de 1,2,3,5,6,7-hexahidro -s-indaceno.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159857A1 (en) * 2010-06-16 2011-12-22 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
US8084620B2 (en) * 2008-12-19 2011-12-27 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2005304473A1 (en) 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
EP1831227B1 (en) 2004-12-17 2013-06-19 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
BRPI0608252A2 (pt) 2005-03-10 2010-04-06 Cgi Pharmaceuticals Inc entidades quìmicas, composições farmacêuticas compreendendo as mesmas, métodos utilizando as referidas entidades quìmicas e uso das referidas entidades quìmicas
CN101268048A (zh) * 2005-09-16 2008-09-17 瑟瑞耐克斯有限公司 咔唑衍生物
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
ES2390135T3 (es) 2005-11-22 2012-11-06 Merck Sharp & Dohme Corp. Compuestos tricíclicos útiles como inhibidores de quinasas
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
CA2663178C (en) 2006-09-11 2016-01-12 Matrix Laboratories Ltd. Dibenzofuran derivatives as inhibitors of pde-4 and pde-10
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
US8431569B2 (en) 2007-12-13 2013-04-30 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
US8318132B2 (en) 2008-02-14 2012-11-27 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological dysfunction
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
EP2151441A1 (en) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
CN102822171B (zh) 2010-03-26 2015-09-02 默克专利有限公司 作为自分泌运动因子抑制剂的苯并萘啶胺类
EP2455378A1 (en) 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
CN103429595B (zh) 2010-11-15 2015-10-21 Viiv保健英国有限公司 Hiv复制的抑制剂
BR112013029620A2 (pt) 2011-05-17 2016-09-06 Hoffmann La Roche inibidores de tirosina quinase de bruton
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8084620B2 (en) * 2008-12-19 2011-12-27 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
WO2011159857A1 (en) * 2010-06-16 2011-12-22 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAN LOU, OWENS TIMOTHY D., KUGLSTATTER ANDREAS, KONDRU RAMA K., GOLDSTEIN DAVID M.: "Bruton’s Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 55, no. 10, 24 May 2012 (2012-05-24), pages 4539 - 4550, XP055080230, ISSN: 00222623, DOI: 10.1021/jm300035p *

Also Published As

Publication number Publication date
MA38648A1 (fr) 2017-09-29
US10106559B2 (en) 2018-10-23
WO2014210085A9 (en) 2015-12-23
TWI648272B (zh) 2019-01-21
CN105358546B (zh) 2017-10-31
PT3013814T (pt) 2017-08-10
TW201536774A (zh) 2015-10-01
UY35625A (es) 2014-12-31
JP2016523907A (ja) 2016-08-12
BR112015030723A2 (pt) 2017-07-25
CL2015003635A1 (es) 2016-07-29
CA2916500A1 (en) 2014-12-31
SI3013814T1 (sl) 2017-08-31
US9850258B2 (en) 2017-12-26
US20140378475A1 (en) 2014-12-25
US20170283438A1 (en) 2017-10-05
US9334290B2 (en) 2016-05-10
AR096721A1 (es) 2016-01-27
ES2636652T3 (es) 2017-10-06
CN105358546A (zh) 2016-02-24
IL243296B (en) 2018-05-31
DK3013814T3 (en) 2017-09-25
TN2015000529A1 (en) 2017-04-06
EP3013814B1 (en) 2017-06-14
CY1119371T1 (el) 2018-02-14
EA201592287A1 (ru) 2016-06-30
WO2014210085A1 (en) 2014-12-31
LT3013814T (lt) 2017-08-10
PH12015502630A1 (en) 2016-03-07
SMT201700422T1 (it) 2017-11-15
US20160194338A1 (en) 2016-07-07
JP6353529B2 (ja) 2018-07-04
KR20160022889A (ko) 2016-03-02
US20180079758A1 (en) 2018-03-22
US20190382416A1 (en) 2019-12-19
RS56371B1 (sr) 2017-12-29
MA38648B1 (fr) 2018-06-29
BR112015030723A8 (pt) 2020-01-07
MY176631A (en) 2020-08-19
US10435415B2 (en) 2019-10-08
PL3013814T3 (pl) 2017-11-30
PE20160519A1 (es) 2016-05-21
KR102346508B1 (ko) 2022-01-03
US20190023719A1 (en) 2019-01-24
HRP20171031T1 (hr) 2017-10-06
HK1223359A1 (en) 2017-07-28
AU2014302548A1 (en) 2016-02-11
AU2014302548B2 (en) 2018-05-10
HUE034460T2 (en) 2018-02-28
EP3013814A1 (en) 2016-05-04

Similar Documents

Publication Publication Date Title
EA026729B1 (ru) Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения
EP3461821B1 (en) Indole carboxamide compounds useful as kinase inhibitors
EP3013815B1 (en) Carbazole carboxamide compounds useful as kinase inhibitors
JP2006503845A (ja) Ｃｂ２受容体モジュレーターとしてのピリジン誘導体
CA2979222A1 (en) Triazolyl pyrimidinone compounds as pde2 inhibitors
HK1223359B (en) Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors
JPH07238071A (ja) 置換アミノ基を有する新規キノリン誘導体

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU